undamentalytics Newsletter
Sign in

Amneal Pharmaceuticals, Inc. revenue

Amneal Pharmaceuticals, Inc.'s revenue was $3.02bn in fiscal 2025, up 8.0% on the year before. Since fiscal 2016 ($1.02bn) it has grown at a compound 12.8% a year. Over the last twelve months it was $3.12bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,0181,0341,6631,6261,9932,0942,2122,3942,7943,0193,118
Growth on the year before—+1.5%+60.9%−2.2%+22.5%+5.1%+5.7%+8.2%+16.7%+8.0%—
Gross profit5975267163536287697858211,0201,1131,226
Gross margin58.7%50.9%43.1%21.7%31.5%36.7%35.5%34.3%36.5%36.9%39.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue YoY
Av KARE $745M ▲ 12.3%
Specialty $529M ▲ 18.6%

These categories overlap or exclude eliminations, so shares aren't shown.

From Amneal Pharmaceuticals, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Amneal Pharmaceuticals, Inc. $3.12bn 9.3% 10.5%
Royalty Pharma plc $2.54bn 10.0% 2.4%
Jazz Pharmaceuticals plc $4.72bn 13.5% 7.5%
Elanco Animal Health Inc $5.02bn 12.0% 5.1%
Organon & Co. $6.10bn -3.2% -0.3%
Lantheus Holdings, Inc. $1.56bn 2.3% 11.4%

Compare with peers

Head to head: AMRX vs RPRXAMRX vs JAZZAMRX vs ELAN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amneal Pharmaceuticals, Inc.